CAH — Cardinal Health, Inc.

As of 2026-09-13 the Street is bullish on the FY2026 results delivered 8/11/26: Q4 adjusted EPS rose ~40% YoY, FY26 revenue reached ~$254B (+14%) with ~30% adjusted operating earnings growth to ~$3.6B, FY27 guidance targets ~14% adjusted EPS growth, and the board added $5.0B to the buyback (total $6.4B) after a $350M accelerated repurchase. Ten analysts carry a consensus Buy with an average target of $273.22 (range $250-$292), and the shares had rallied ~29% over the prior four months into late summer. Two honest caveats: the week into 2026-09-13 was -5.1% with RSI at 47.1, i.e. momentum cooling right under the $258.30 high; and the FMP rating breakdown (0 strong buy / 18 buy / 15 hold) is noticeably more muted than the '14-15 strong buys' framing in the news flow - a real 15 holds is a lot of side-line money at 18.7x forward earnings.

Revenue growth is decelerating hard, but for a benign reason. YoY revenue: Q1 FY26 (Sep-25) $64.0B, +22.4%; Q2 (Dec-25) $65.4B, +18.4%; Q3 (Mar-26) $60.9B, +11.0%; Q4 (Jun-26) $63.9B, +6.1% - a clean straight-line slowdown. That tracks falling wholesale acquisition costs under IRA drug-pricing changes, not weak unit demand, and the margin line confirms it: gross profit rose +21.9%, +13.9%, +17.7% and +24.7% YoY across those same four quarters, with Q4 gross margin at 4.30% vs 3.66% a year earlier. FY26 revenue was ~$254B (+14%) and GAAP operating income $2.61B vs $2.28B (+14.9%), though management reported adjusted operating earnings up ~30% to ~$3.6B - a ~$1B exclusion bridge that is the single biggest quality-of-earnings question here. EPS was lumpy: $1.88, $1.97, a soft $1.69 in Q3 (operating income fell to $509M from $730M) before Q4 stabilized at $1.69 with operating income back to $729M; FY26 GAAP EPS $7.23 vs $6.45 in FY25 (+12%), TTM $7.263. Cash is the standout: FY26 free cash flow $4.53B vs $1.85B in FY25 and $3.25B in FY24, albeit with violent working-capital swings (Sep-24 -$1.74B and Dec-24 -$0.50B quarters). Structural read: the mix shift into specialty, nuclear and at-home care is genuinely expanding gross margin; the top line is shrinking in price terms by design.

Fair-to-full, not cheap. As of 2026-09-13 the stock traded at 32.3x trailing GAAP EPS of $7.263 (vs a 5-year average P/E of 40.4, itself inflated by opioid-era charges), 2.61x PEG, and 0.216x sales versus a 5-year average P/S of just 0.14 - a ~54% premium to its own history. On the $12.544 FY2027 consensus EPS the forward P/E is 18.7x, which is reasonable IF you accept an adjusted number that sits far above GAAP earnings; that same EPS would require a ~73% jump from the $7.26 TTM print. The debt-adjusted picture is less kind: EV/EBITDA screens at ~17.4x, rich for a business with 3.8% gross margins, 1.0% operating margins, and a 13.2% ROIC. P/B (-19.2x), ROE (-59.5%) and D/E are unusable because book equity is -$2.88B. Net: the multiple has expanded faster than earnings, and the 52-week range (145.87-258.30) says the market has already re-rated this name hard.

The market is pricing in the mid-teens adjusted EPS growth path, the specialty/nuclear/at-home margin mix, and the buyback - not a reacceleration in revenue. At the 2026-09-13 close of $234.57 you are paying 18.7x the FY27 consensus $12.544 and ~25-26x a more conservative ~$9 GAAP-consistent run-rate. So the asymmetry is skewed: with management guiding only ~4% revenue and ~14% adjusted EPS growth for FY2027, the stock needs multiple stability to work - a de-rating to 16x FY27 consensus alone would take it to roughly $200. Upside surprise has to come from gross-margin mix and buyback accretion, not the top line, and the wide adjusted-vs-GAAP bridge means 'beat' headlines may not convert into GAAP earnings. Conversely, if the ~$1B of excluded items shrink, GAAP EPS closes the gap toward adjusted and the valuation looks materially less stretched - that is the real bull case, and it is not in the deterministic score.

As of 2026-09-13: RSI(14) 47.1 (dead neutral), price $234.57 vs SMA20 -1.09% (below), vs SMA50 +0.13% (flat), vs SMA200 +8.42% (well above). Returns: -5.1% 1-week, +0.18% 1-month, +4.79% 3-month, +8.06% 6-month. The read is a longer-term uptrend that has lost short-term momentum just under the 52-week high of $258.30 - the 20-day has rolled over and the 50-day (~$234) is the line in the sand. Not oversold, not overbought; beta of 0.52 means it is not a name that tends to crash. Entry-timing implication: no urgency to buy here. A flush toward the 200-day with RSI in the mid-30s is the better risk/reward setup; chasing a flat 50-day into a decelerating top line is not.

• IRA drug-pricing reform: lower wholesale acquisition costs cut reported revenue (YoY growth slid from +22.4% in Q1 FY26 to +6.1% in Q4) without cutting unit volumes - a mechanical top-line drag that will keep headline revenue growth in the ~3-5% guided range.
• Tariffs and input costs: the Global Medical Products segment absorbed roughly $200M of tariff-related costs in FY2026, compressing that segment's gross profit even as the overall company margin expanded.
• Demographics and utilization: aging population and rising prescription volumes are a durable volume tailwind for a distributor with fixed-cost infrastructure.
• Mix shift to higher-margin care: specialty pharma, nuclear medicine and at-home services are structurally lifting gross margin (Q4 FY26 4.30% vs 3.66% YoY) - unusual for distribution and the core of the re-rating thesis.
• Rates and balance-sheet structure: $6.86B of long-term debt (down from $8.98B at 9/30/25), $4.86B cash, negative book equity of -$2.88B, and a 0.883 current ratio mean refinancing costs and buyback capacity are rate-sensitive; beta of 0.52 keeps it a defensive holding in risk-off tape.

• Q1 FY2027 earnings on October 29, 2026 - first hard read on the ~14% adjusted EPS growth guide, organic volume growth, and integration of the Strive Medical and AdaptHealth Diabetes Health tuck-ins.
• Fall healthcare conferences (Morgan Stanley, Baird, Wells Fargo, mid-September 2026) - management visibility into the specialty/at-home/nuclear strategy and any update to long-range margin targets.
• Capital return: $6.4B total buyback authorization including a $350M accelerated share repurchase, plus the 0.861% dividend - direct EPS accretion at a 234M share count.
• Continued tuck-in M&A in high-margin at-home and specialty care, and evidence that the ~$1B GAAP-to-adjusted operating bridge is narrowing (which would raise GAAP EPS without any change in the business).

• Earnings quality: FY26 GAAP operating income of $2.61B versus management's ~$3.6B adjusted is a ~$1B exclusion base on a company with 1.0% operating margins - the headline growth rate is softer than it looks.
• Structural margin fragility: 3.8% gross margin and 1.0% operating margin mean a small pricing or mix error swings net income hard; Q3 FY26 operating income already fell to $509M from $730M YoY before rebounding.
• Revenue deceleration and generic/IRA WAC deflation: YoY growth has fallen from +22.4% to +6.1% in four quarters and management guides ~4% for FY27 - if volumes soften on top of price deflation, the top line could stall.
• Balance sheet: -$2.88B stockholders' equity, 0.883 current ratio, 0.489 quick ratio and $6.86B long-term debt leave little cushion; customer concentration in Pharmaceutical Distribution is an ongoing structural exposure.
• Valuation/de-rating risk: EV/EBITDA ~17.4x, P/S 0.216 vs 0.14 five-year average, and a price only ~9% below the 52-week high while the 200-day sits 8.4% lower - multiple compression, not fundamentals, is the most likely source of a 15-20% drawdown.

FY2026 was a genuinely good year - ~$254B revenue, $4.53B of free cash flow, gross margin up ~64bps in Q4, a ~30% jump in adjusted operating earnings, and a real mix shift into higher-margin specialty, nuclear and at-home care. But at $234.57 on 2026-09-13 you are paying 18.7x a FY2027 consensus EPS that requires a ~73% jump from TTM GAAP earnings, and the stock sits 54% above its own five-year average P/S near the top of its 52-week range. The business is fine; the price already reflects it. I would not be a buyer here - I would want either a pullback toward the 200-day with RSI in the 30s, or evidence the $1B adjusted-vs-GAAP gap is closing.

Weighted blend of three methods, all run off 2026-09-13 data: 50% weight to 19.5x FY2027 consensus EPS of $12.544 ($244.61), a modest discount to the Street's implied ~21.8x given the wide adjusted-vs-GAAP bridge; 30% to capitalizing the three-year average free cash flow of $3.21B (FY24 $3.25B, FY25 $1.85B, FY26 $4.53B) at a 5.25% required FCF yield ($260.80, on 234.2M shares); and 20% to 16x EV/EBITDA on ~$3.26B EBITDA less $2.01B net debt ($214.40). Weighted result is $243.43, implying ~19.4x FY27 consensus EPS and about 3.6% above the $234.57 close.